Lates News

Chen Zhu, Chief Analyst of Medical Health Industry at Citic Securities, stated that in the first half of 2025, the pharmaceutical sector showed the best market returns in the past three years. Benefiting from the improving external environment for medicine and the accelerated harvest period for domestic innovative drugs, it is expected that the performance and valuation recovery trend of the medical health industry in the second half of 2025 will be relatively certain. Many Chinese innovative drug companies have demonstrated strong potential for international expansion and are constantly increasing their asset value through licensing deals and other models to compete in the global innovative drug market.